Journal article
Treatment of Proximal Deep Vein Thrombosis With a Novel Synthetic Compound (SR90107A/ORG31540) With Pure Anti–Factor Xa Activity
Abstract
BACKGROUND: Patients with venous thromboembolism require initial treatment with an immediate-acting anticoagulant, low-molecular-weight heparin. We evaluated a novel synthetic factor Xa inhibitor (SR90107a/ORG31540) as an alternative treatment.
METHODS AND RESULTS: A randomized-parallel-group, phase II trial to assess the efficacy and safety of SR90107a/ORG31540 (5, 7.5, or 10 mg once daily) relative to low-molecular-weight heparin (dalteparin, …
Journal
Circulation, Vol. 102, No. 22, pp. 2726–2731
Publisher
Wolters Kluwer
Publication Date
November 28, 2000
DOI
10.1161/01.cir.102.22.2726
ISSN
0009-7322